GrafoDexia

This site is devoted to copyright and issues of 'intellectual property,' particularly the issue's analytical aspects. It also concerns itself with the gap between public perception and the true facts, and with the significant lag time between the coverage on more technical sites and the mainstream press. For site feed, see: http://grafodexia.blogspot.com/atom.xml To see the list of sites monitored to create this site, see: http://rpc.bloglines.com/blogroll?html=1&id=CopyrightJournal

Sunday, February 13, 2005

Pixar's blockbuster a little smaller this year. It's interesting to compare this to big pharma, where the lack of blockbusters is really starting to hurt. Incredibles is supposed to be quite good, but with a smaller audience than Nemo. In effect, Pixar suffered because they didn't homogenize for a larger audience. There's been much talk in recent years of micro-marketing and sub-segmentation of markets, but when the product costs as many millions as films do, is that really possible? Pharma, on the other hand, steers away from development of drugs that don't have the potential to be blockbusters, due to the high cost of development, with the effect that many promising drugs aren't made. If Pixar takes a lesson from this and focuses only on certain, larger, markets, it will be the first step in the dilution of a great company.

Enterprise fans buy full-page LA Times ad. Still think of TV-watchers as passive consumers?

The semantic game over copyright and peer-to-peer. There were some interesting discussions about this ~2 years ago on a listserv called (most unfortunately) InfoAnarchy.

--Ari

0 Comments:

Post a Comment

<< Home